目的 探讨曲克芦丁脑蛋白水解物注射液联合三磷酸胞苷二钠注射液治疗新生儿缺氧缺血性脑病的临床疗效。方法 选取2016年1月-2017年9月南阳市中心医院儿科收治的86例新生儿缺氧缺血性脑病患儿为研究对象，随机将患儿分为对照组和治疗组，每组各43例。对照组静脉滴注三磷酸胞苷二钠注射液，100 mg加入5%葡萄糖溶液30 mL中，1次/d；治疗组在对照组治疗的基础上静脉滴注曲克芦丁脑蛋白水解物注射液，0.5 mL/（kg·d），将其加入5%葡萄糖溶液50 mL中。轻、中度患儿连续治疗7~14 d，重度患儿连续治疗14~21 d。观察两组临床疗效，比较两组患者的神经体征恢复情况、新生儿行为神经评分法（NBNA）评分、智能发育指数（MDI）评分、运动发育指数（PDI）评分、神经内分泌功能和后遗症发生情况。结果 治疗后，对照组和治疗组的总有效率分别为81.4%、97.7%，两组比较差异具有统计学意义（P<0.05）。治疗后，治疗组意识恢复时间、反射恢复时间、肌张力恢复时间均显著短于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后7、14 d，两组NBNA评分均显著提高，同组治疗前后比较差异具有统计学意义（P<0.05）。且治疗组NBNA评分显著高于对照组，两组比较差异具有统计学意义（P<0.05）。出生后6个月，两组MDI、PDI评分均显著高于出生后3个月，同组比较差异具统计学意义（P<0.05）。出生后3、6个月后，治疗组MDI、PDI评分均显著高于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血清皮质醇（COR）、去甲肾上腺素（NE）水平均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）。治疗后，治疗组血清COR、NE水平均显著低于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，治疗组后遗症发生率为4.7%，略低于对照组的7.0%，但两组比较无统计学差异。结论 曲克芦丁脑蛋白水解物注射液联合三磷酸胞苷二钠注射液可显著改善新生儿缺氧缺血性脑病患儿的神经功能，提高生活质量，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Troxerutin and Cerebroprotein Hydrolysate Injection combined with Cytidine Disodium Triphosphate Injection in treatment of neonatal hypoxic-ischemic encephalopathy. Methods Children (86 cases) with neonatal hypoxic-ischemic encephalopathy in Nanyang City Center Hospital from January 2016 to September 2017 were randomly divided into control and treatment groups, and each group had 43 cases. Children in the control group were iv administered with Cytidine Disodium Triphosphate Injection, 100 mg added into 5% glucose solution 30 mL, once daily. Children in the treatment group were iv administered with Troxerutin and Cerebroprotein Hydrolysate Injection on the basis of the control group, 0.5 mL/(kg·d), added into 5% glucose solution 50 mL. Mild and moderate children in two groups were treated for 7-14 d, but severe children in two groups were treated for 14-21 d. After treatment, the clinical efficacy was evaluated, and the NBNA scores, MDI scores, PDI scores, neuroendocrine function, and the occurrence of sequelae in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment group were 81.4% and 97.7%, respectively, and there were differences between two groups (P<0.05). After treatment, the recovery times of consciousness, reflex, and muscle tension in the treatment group were significantly shorter than those in the control group, with significant difference between two groups (P<0.05). After treatment of 7, 14 d, the NBNA scores in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the NBNA scores in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After birth of 6 months, the MDI and PDI scores in two groups were significantly higher than those in the birth of 3 months, and the difference was statistically significant in the same group (P<0.05). After birth of 3 and 6 months, the MDI and PDI scores in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, serum levels of COR and NE in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, the serum levels of COR and NE in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the incidence of sequelae in the treatment group was 4.7%, which was slightly lower than 7.0% in the control group, but there was no statistical difference between two groups. Conclusion Troxerutin and Cerebroprotein Hydrolysate Injection combined with Cytidine Disodium Triphosphate Injection can significantly improve the neurological function and quality of life of neonates with neonatal hypoxic-ischemic encephalopathy, which has a certain clinical application value.